Editorial Office and Clinical Cancer Bulletin

The dawn of RAS-targeted therapy: a landmark breakthrough of daraxonrasib in pancreatic cancer

Daraxonrasib, a novel RAS-targeted therapy, has been approved for adults with metastatic pancreatic adenocarcinoma. Clinical trials have shown a median overall survival of 13.2 months and nearly three times the objective response rate compared to chemotherapy. The medication targets KRAS, NRAS, and HRAS mutations, covering over 90% of ...

SourceEditorial Office and Clinical Cancer Bulletin·JournalClinical Cancer Bulletin·TypeCommentary/editorial·DateSep 16, 2026

Brain structure differences may explain striking ancestry gaps in blood cancers

A new study reveals that specific features of the human cerebral cortex are causally linked to multiple myeloma and chronic lymphocytic leukemia, differing between ancestries. Genetic variants favoring larger pars triangularis surface area and thicker frontal cortices are found in Western populations.

SourceEditorial Office and Clinical Cancer Bulletin·JournalClinical Cancer Bulletin·TypeData/statistical analysis·DateApr 29, 2026